featured
Pembrolizumab as a First-Line Treatment for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Clinical Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Am J Clin Dermatol 2024 Oct 08;[EPub Ahead of Print], L Mortier, L Villabona, B Lawrence, A Arance, MO Butler, M Beylot-Barry, P Saiag, M Samimi, PA Ascierto, F Spada, M De Pontville, M Maio, A Berrocal, E Espinosa, J Capdevila, M Levin, D Das, C Krepler, D Grebennik, V Chiarion-SileniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.